Anticancer Agents in Combination with Statins
نویسندگان
چکیده
منابع مشابه
The statins as anticancer agents.
1,072,503 person-year of follow-up, 195,594 patients died: 162,067 from cancer, 14,489 from cardiovascular causes and 19,038 from other causes. Among patients, 40 years and older, 18,721 received statins before cancer diagnosis and 277. 204 had never used statins. All cause mortality among patients with cancer taking statins was reduced by 15%, and only by 10% as risk for death from cardiovascu...
متن کاملThe statins as anticancer agents.
3-Hydroxy-3-methylgutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there are emerging interests in their use as anticancer agents based on preclinical evidence of their antiproliferative, proapoptotic, anti-invasive, and radiosensitizing properties. Inhibition of 3-hydroxy-3-methylgutary...
متن کاملPotential antagonism of tubulin-binding anticancer agents in combination therapies.
ZD6126 is a vascular targeting agent, developed for the treatment of solid tumors. In vivo, ZD6126 is rapidly converted into the tubulin-binding agent N-acetylcolchinol. We have previously reported that in vitro N-acetylcolchinol disrupts microtubules and induces rapid changes in endothelial cell morphology, which in a tumor would lead to a rapid loss of tumor vessel integrity and subsequent ex...
متن کاملRadiation Recall with Anticancer Agents
Radiation recall is an acute inflammatory reaction confined to previously irradiated areas that can be triggered when chemotherapy agents are administered after radiotherapy. It remains a poorly understood phenomenon, but increased awareness may aid early diagnosis and appropriate management. A diverse range of drugs used in the treatment of cancer has been associated with radiation recall. As ...
متن کاملStatins as immunomodulatory agents.
Statins have long been thought to exert their benefits by reducing cholesterol synthesis. However, the fact that mevalonate is the precursor of isoprenoids that regulate diverse cellular functions has led investigators to examine pleiotropic effects for these agents. Major histocompatibility complex class II (MHC-II) molecules, which affect the immune response and organ rejection after transpla...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Bioequivalence & Bioavailability
سال: 2017
ISSN: 0975-0851
DOI: 10.4172/jbb.1000345